Plain-English translation of NCT05887271 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a low-calorie meal replacement plan (MRP) to help people with preserved ejection fraction heart failure—a condition where the heart doesn't pump blood out as forcefully as it should, making exercise difficult. The meal plan provides 850 calories per day through prepared meals and is supported by dieticians and doctors who monitor your health throughout the study. Early research suggests that weight loss through this approach may help reverse some of the heart changes that occur with this condition.
Many people with this type of heart failure have very limited treatment options and struggle with exercise intolerance and poor quality of life. Previous studies in smaller groups showed that weight loss through the meal replacement plan may help, so this larger, more diverse trial aims to confirm whether this treatment truly works for a broader group of patients.
You will be randomly assigned to one of two groups. If you are in the meal replacement group, you will receive 3–4 prepared meals per day (totaling 850 calories) supplied by a company called Counterweight, along with regular support from research dieticians and a study clinician who will monitor your health and medications. If you are in the comparison group, you will receive standard heart failure and dietary advice for 12 weeks, and then you will have the option to try the meal replacement plan yourself. The trial takes place over 12–24 weeks at one of four sites (Leicester, Manchester, Leeds, or Oxford), with regular visits to measure your exercise ability, symptoms, quality of life, and heart function.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United Kingdom